| scholarly article | Q13442814 |
| P2093 | author name string | Tatsuo Miyamura | |
| Masato Nakamura | |||
| Osamu Yokosuka | |||
| Tatsuo Kanda | |||
| Shuang Wu | |||
| Shingo Nakamoto | |||
| P2860 | cites work | Antibody-Dependent Enhancement of Hepatitis C Virus Infection | Q27485451 |
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease | Q28483964 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials | Q34100819 | ||
| Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients | Q34103218 | ||
| New antiviral therapies for chronic hepatitis C | Q34130399 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites | Q34323105 | ||
| Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment | Q34606147 | ||
| Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications | Q34674780 | ||
| Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. | Q35095217 | ||
| Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin | Q36246785 | ||
| Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. | Q37135105 | ||
| APASL consensus statements and management algorithms for hepatitis C virus infection. | Q38552131 | ||
| Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. | Q40707649 | ||
| Immunopathology of hepatitis C. | Q41574267 | ||
| Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up | Q42271121 | ||
| An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen | Q42985987 | ||
| Hepatitis C in Patients Undergoing Liver Transplantation | Q42986420 | ||
| Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options | Q42986593 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. | Q42991111 | ||
| Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection | Q42992027 | ||
| Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study | Q42994755 | ||
| Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test | Q43031605 | ||
| Significance of specific antibody assay for genotyping of hepatitis C virus | Q43035715 | ||
| Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. | Q43040757 | ||
| Interferon-induced chronic active hepatitis? | Q43466582 | ||
| Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. | Q44657843 | ||
| Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. | Q45206663 | ||
| Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C | Q45294209 | ||
| Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients | Q45387928 | ||
| Acute hepatitis C virus infection, 1986-2001: a rare cause of fulminant hepatitis in Chiba, Japan. | Q45651838 | ||
| Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients | Q46758127 | ||
| Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. | Q50547517 | ||
| Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. | Q50556902 | ||
| A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. | Q52010912 | ||
| Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C | Q72281870 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | L-alanine | Q218642 |
| ribavirin | Q421862 | ||
| P304 | page(s) | 1015-1021 | |
| P577 | publication date | 2013-06-15 | |
| P1433 | published in | International Journal of Medical Sciences | Q10927439 |
| P1476 | title | Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment | |
| P478 | volume | 10 |
| Q37358287 | IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase |
| Q35947900 | Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? |
| Q35069533 | No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV |
| Q33769085 | Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response |
| Q35903139 | Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype |
Search more.